Comparing BioNexus Gene Lab (NASDAQ:BGLC) & Hudson Technologies (NASDAQ:HDSN)

Hudson Technologies (NASDAQ:HDSN) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap industrials companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Institutional and Insider Ownership

71.3% of Hudson Technologies shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 1.9% of Hudson Technologies shares are owned by company insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Hudson Technologies and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hudson Technologies	-0.54%	0.80%	0.61%
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

Earnings & Valuation

This table compares Hudson Technologies and BioNexus Gene Lab”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hudson Technologies	$242.33 million	0.77	$16.67 million	($0.02)	-222.50
BioNexus Gene Lab	$7.43 million	0.34	-$2.98 million	($1.26)	-0.69

Hudson Technologies has higher revenue and earnings than BioNexus Gene Lab. Hudson Technologies is trading at a lower price-to-earnings ratio than BioNexus Gene Lab, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Hudson Technologies and BioNexus Gene Lab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hudson Technologies	2	1	2	0	2.00
BioNexus Gene Lab	1	0	0	0	1.00

Hudson Technologies presently has a consensus target price of $7.00, suggesting a potential upside of 57.30%. Given Hudson Technologies’ stronger consensus rating and higher possible upside, research analysts clearly believe Hudson Technologies is more favorable than BioNexus Gene Lab.

Volatility and Risk

Hudson Technologies has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.28, meaning that its share price is 328% more volatile than the S&P 500.

Summary

Hudson Technologies beats BioNexus Gene Lab on 12 of the 14 factors compared between the two stocks.

About Hudson Technologies

Hudson Technologies, Inc. (NASDAQ:HDSN) provides refrigerant products and services for the heating, ventilation, air conditioning and refrigeration (HVACR) industry. The company supplies reclaimed and recycled refrigerants, as well as virgin refrigerants and related products, to customers that operate or service commercial, industrial and residential cooling systems. Its services include refrigerant reclamation, refrigerant management, cylinder management, technical support and logistics. Hudson also provides RefrigerantSide Services, which are designed to help customers recover, analyze, replace and manage refrigerants at industrial and commercial facilities.

About BioNexus Gene Lab

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and molecular diagnostics company focused on using genetic and genomic information to support disease screening, risk assessment and personalized healthcare. The company develops and commercializes diagnostic products and laboratory services based on the analysis of biological samples, including blood and other specimens. Its offerings are intended to help identify potential health risks and support the early detection and management of conditions such as cancer and other diseases.